JP2024540172A - 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法 - Google Patents

心血管状態を処置するための方法および心臓の代謝効率を増大させる方法 Download PDF

Info

Publication number
JP2024540172A
JP2024540172A JP2024525619A JP2024525619A JP2024540172A JP 2024540172 A JP2024540172 A JP 2024540172A JP 2024525619 A JP2024525619 A JP 2024525619A JP 2024525619 A JP2024525619 A JP 2024525619A JP 2024540172 A JP2024540172 A JP 2024540172A
Authority
JP
Japan
Prior art keywords
imb
dose
compound
subjects
trimetazidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540172A5 (https=
Inventor
ジャイクリシュナ パテル，
ポール チェンバリン，
Original Assignee
インブリア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インブリア ファーマシューティカルズ， インコーポレイテッド filed Critical インブリア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024540172A publication Critical patent/JP2024540172A/ja
Publication of JP2024540172A5 publication Critical patent/JP2024540172A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2024525619A 2021-11-01 2022-10-31 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法 Pending JP2024540172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274389P 2021-11-01 2021-11-01
US63/274,389 2021-11-01
PCT/US2022/048401 WO2023076665A1 (en) 2021-11-01 2022-10-31 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism

Publications (2)

Publication Number Publication Date
JP2024540172A true JP2024540172A (ja) 2024-10-31
JP2024540172A5 JP2024540172A5 (https=) 2025-10-16

Family

ID=86158627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525619A Pending JP2024540172A (ja) 2021-11-01 2022-10-31 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法

Country Status (9)

Country Link
US (1) US20250235447A1 (https=)
EP (1) EP4426301A4 (https=)
JP (1) JP2024540172A (https=)
KR (1) KR20240095326A (https=)
CN (1) CN118647381A (https=)
AU (1) AU2022376557A1 (https=)
CA (1) CA3236328A1 (https=)
IL (1) IL312523A (https=)
WO (1) WO2023076665A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054580A1 (en) * 2023-09-08 2025-03-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
TWI683808B (zh) * 2017-07-18 2020-02-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有胺或(硫)醯胺之lxr調節劑
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Also Published As

Publication number Publication date
US20250235447A1 (en) 2025-07-24
WO2023076665A1 (en) 2023-05-04
EP4426301A1 (en) 2024-09-11
AU2022376557A1 (en) 2024-05-02
CN118647381A (zh) 2024-09-13
CA3236328A1 (en) 2023-05-04
KR20240095326A (ko) 2024-06-25
IL312523A (en) 2024-07-01
EP4426301A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
AU2018204499B2 (en) Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Chapman et al. Cilostazol: a review of its use in intermittent claudication
Chonchol et al. Serum phosphorus and cardiovascular mortality in type 2 diabetes
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
Karamat et al. The acute effect of beta‐guanidinopropionic acid versus creatine or placebo in healthy men (ABC‐Trial): a randomized controlled first‐in‐human trial
JP2024540172A (ja) 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法
Mayadunne et al. Long‐term effects of metformin on offspring health: A review of current evidence and future directions
Aronow et al. Effect of halofenate on serum uric acid
WO2021242758A1 (en) Improved nitro-fatty acid oral dose regimens
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
KR20230028535A (ko) 트리메타지딘의 변형 형태의 변형 방출 제제
CA2304899C (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
Extremera et al. Clinical Trials on Diabetes Mellitus
Agent Pr PRO-PIOGLITAZONE
Agent KOMBOGLYZE®
Agent Pr AURO-PIOGLITAZONE
Omaira et al. Insulinemia: relation with obesity and high blood pressure
Standard et al. PrACCEL PIOGLITAZONE
HK1260063B (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester
Agent PrVAN-Pioglitazone

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251007